Floatz logo

Ketorolac Tromethamine

Oropharyngeal Cancer

National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Oropharyngeal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2BB
Fludarabine
HRYZ Biotech Co.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
Epirubicin
Inhibrx Biosciences, Inc
Phase 2B
Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2B

View all 24 →

Same molecule, other indications

Ketorolac Tromethamine is also rated in:

migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
Hematological Malignancy (Leukemia- Lymphoma)Dormant
BB
Indicative ·
70 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →